Explore

explore arrow

Explore

Targeting Cancer at the
Source of the Disease

Learn about our approach

Overcoming Persistent Hurdles in Oncology

At Sapience, we think boldly about the possibilities for treating cancer, providing new options for patients that address the disease where it forms. We are developing first-in-class peptide antagonists against the most elusive oncogenic and immune-modulating drug targets.

home-img-01

Advancing Intelligently-Designed Therapeutics

We are pioneering a new class of peptide antagonists called SPEARs™ (Stabilized Peptides Engineered Against Regulation). SPEARs hold the potential to combine the best properties of small molecules and antibodies in disrupting oncogenic and immune regulation – allowing us to address cancer at the source of disease. Two of our SPEARs, ST101 and ST316, are recruiting clinical studies in patients with advanced solid tumors.

home-img-02

Recent News

arrow right

Sapience Therapeutics to Present at the 2024 BIO CEO & Investor Conference

February 13, 2024Read More

Sapience Therapeutics Presents New ST101 Phase 2 Clinical Data in GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

November 17, 2023Read More

Sapience Therapeutics Announces Poster Presentation with New Clinical Data for ST101 in GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

November 1, 2023Read More

Sapience Therapeutics Presents ST101 Clinical Data and ST316 Preclinical Data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 13, 2023Read More

Sapience Therapeutics Announces Presentation of ST101 Clinical Data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 20, 2023Read More

Sapience Therapeutics Announces First Patient Dosed in Phase 1-2 Clinical Study of its First-in-Class β-catenin Antagonist, ST316, in Advanced Solid Tumors

June 13, 2023Read More

Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist

May 4, 2023Read More

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

April 14, 2023Read More

Sapience Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 5, 2023Read More

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 16, 2023Read More

Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors

March 14, 2023Read More

Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day

January 26, 2023Read More

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer

December 1, 2022Read More

Sapience Therapeutics to Participate in Upcoming Investor Conferences

November 21, 2022Read More

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting

November 14, 2022Read More

Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 10, 2022Read More

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy, Long-Term Exposure and Safety in Phase 1-2 at 34th EORTC-NCI-AACR Symposium

October 13, 2022Read More

Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 12, 2022Read More

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer

October 4, 2022Read More

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics

September 19, 2022Read More

Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients

August 8, 2022Read More

Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences

July 28, 2022Read More

Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors

June 3, 2022Read More

Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)

June 2, 2022Read More

Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions

May 31, 2022Read More

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022

May 12, 2022Read More

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

May 3, 2022Read More

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways

April 11, 2022Read More

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs

March 31, 2022Read More

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

March 15, 2022Read More

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 9, 2022Read More

Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel

February 15, 2022Read More

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference

February 3, 2022Read More

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

January 6, 2022Read More

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma

December 15, 2021Read More

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium

December 9, 2021Read More

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

December 6, 2021Read More

Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference

December 1, 2021Read More

Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 10, 2021Read More

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research

October 29, 2021Read More

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program

October 12, 2021Read More

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021

October 4, 2021Read More

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021

September 13, 2021Read More

Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101

July 29, 2021Read More

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

July 15, 2021Read More

Sapience Therapeutics to Present at BIO Digital 2021

June 9, 2021Read More

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models

May 27, 2021Read More

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases

May 18, 2021Read More

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021

April 6, 2021Read More

Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley

March 4, 2021Read More

Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors

December 1, 2020Read More

Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath

November 19, 2020Read More

Sapience Therapeutics Completes $14 million Preferred Stock Financing

November 17, 2020Read More

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute

August 19, 2020Read More

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors

August 12, 2020Read More

Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II

June 17, 2020Read More

Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications

June 2, 2020Read More

Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications

May 7, 2020Read More

Sapience Therapeutics to Present at Biotech Showcase 2020

January 7, 2020Read More

Sapience Therapeutics to Present at the 2019 Life Sciences Summit

October 29, 2019Read More

Sapience Therapeutics to Present at the 2019 BIO Investor Forum

September 10, 2019Read More

Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer

September 4, 2019Read More

Sapience Therapeutics to Present at the 2019 BIO International Convention

May 16, 2019Read More

Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting

March 14, 2019Read More

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference

January 31, 2019Read More

Sapience Therapeutics to Present at Biotech Showcase 2019

December 11, 2018Read More

Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge

June 26, 2018Read More

Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath

April 5, 2018Read More

Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors

May 10, 2017Read More

Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma

March 29, 2017Read More

Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors

September 7, 2016Read More

Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment

July 20, 2016Read More

Sapience Therapeutics Completes $22.5 Million Series A Financing

July 12, 2016Read More
empty
arrow right